Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-X Study for Non-Radiographic Axial Spondyloarthritis

 Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-X Study for Non-Radiographic Axial Spondyloarthritis

Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-X Study for Non-Radiographic Axial Spondyloarthritis

Shots:

  • The P-III COAST-X study involves assessing of Taltz (ixekizumab) vs PBO in patients with non-radiographic axial spondyloarthritis (nr-axSpA) who are biologic disease-modifying anti-rheumatic drug (bDMARD) naive for 52wks.
  • The P-III COAST-X study results:  @16 & 52wks. met its 1Eps & 2Eps; improvement in the signs and symptoms of nr-axSpA; improvement in ASDAS & BASDAI; patients achieve low disease activity (ASDAS <2.1); improvement in SIJ; improvement in SF-36 Physical Component Summary (PCS) score; no new safety signals observed
  • Taltz (ixekizumab) is a mAb, targeting interleukin 17A (IL-17A) cytokine by inhibiting its interaction with the IL-17 receptor and is under FDA review for radiographic axSpA with its expected regulatory action in H2’19

Click here to read full press release/ article | Ref: Eli Lilly | Image: Fortune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post